Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Aspire Biopharma Holdings, Inc. (ASBP) had Consolidated Net Income/Loss of $-1.98M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.98M |
|
-- |
|
-- |
|
$0.80M |
|
$-0.80M |
|
$-1.18M |
|
$-1.98M |
|
$-1.98M |
|
$-1.98M |
|
$-1.98M |
|
|
Consolidated Net Income/Loss |
$-1.98M |
$-1.98M |
|
$-0.80M |
|
$-0.80M |
|
49.33M |
|
49.33M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$0.99M |
|
-- |
|
-- |
|
$0.99M |
|
$10.56M |
|
-- |
|
$0.05M |
|
$10.61M |
|
$-9.62M |
|
$-9.62M |
|
$-9.62M |
|
49.53M |
|
| Cash Flow Statement Financials | |
$-2.89M |
|
-- |
|
$3.09M |
|
$0.00M |
|
$0.21M |
|
$0.20M |
|
$14.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.09 |
|
-- |
|
-- |
|
-- |
|
-0.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.89M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
20.60% |
|
20.60% |
|
-200.25% |
|
20.60% |
|
$-0.19 |
|
$-0.06 |
|
$-0.06 |
|